Follow The Filings

TSHA Taysha Gene Therapies Inc.

Health Care, filed as TAYSHA GENE THERAPIES INC (COM SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

  • 3 Owners
  • Max 1.0%
  • $20M
  • 1 add 2 reduce

In 2026 Q3 Polen Capital Management added to Taysha Gene Therapies, while Palo Alto Investors and Farallon Capital Management trimmed.

Who owns this now

Largest portfolio weights among holders, up to 1.0% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 0.97%
  2. Farallon Capital Management Reduce 0.05%
  3. Polen Capital Management Add 0.03%

Who owns TSHA

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 0.05%, was 0.07% Reduce 0.0% 2,249,000 $11M History
Palo Alto Investors 0.97%, was 1.3% Reduce −3.9% 1,337,217 $6.5M History
Polen Capital Management 0.03% Add +2.9% 503,379 $2.5M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TSHA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TSHA insider trades
  • None no insider bought on the open market
  • $1.7M sold by 1 insider outside a trading plan
  • $3.1M sold by 1 insider under 10b5-1 plans
  1. Sukumar Nagendran President and Head of R&D
    Planned sale
    $1.2M 200,000 shares at $6.24 18% of stake
    Traded Jul 10 Filed Jul 10
  2. Sukumar Nagendran President and Head of R&D
    Planned sale
    $892K 200,000 shares at $4.46 15% of stake
    Traded Apr 10 Filed Apr 13
  3. Sukumar Nagendran President and Head of R&D
    Planned sale
    $942K 200,000 shares at $4.71 17% of stake
    Traded Jan 12 Filed Jan 14
  4. Sukumar Nagendran President and Head of R&D
    Sale
    $1.7M 370,172 shares at $4.58 27% of stake
    Traded Nov 28, 2025–Dec 1, 2025 Filed Dec 1, 2025

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants, 7 sales to cover taxes, and 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
424B5
8-K 1.01,8.01,9.01
424B5
8-K 7.01,8.01,9.01
8-K 5.07
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.45M $8.33M $9.77M
Net income -$111.57M -$89.3M -$109M
Net margin * -722.1% -1071.6% -1115.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $149.87M $142.13M $324.65M
Total non-current assets * $22.86M $18.23M $18.67M
Total assets $172.73M $160.36M $343.32M
Total current liabilities $36.76M $26.23M $26.55M
Total non-current liabilities * $61.04M $62.61M $69.83M
Total equity $74.94M $71.52M $246.94M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$73.02M -$81.22M -$93.09M
Cash from investing -$7.35M -$0.363M -$0.604M
Cash from financing $136.39M $76.68M $274.59M
Net change in cash $56.02M -$4.9M $180.9M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf